Loading…
Employees: 2,551
Size Doctorglasses Chain (300622.SZ) is a China Health Care company (Medical Specialties) with a market value of $757M, the 2883rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.92 on 6 Nov 2026.
Performance Over six months the shares fell 10.1%, against -9.0% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 6.0% over the last twelve months (peer median +14.1%); the operating margin is 14.3% (peer median 9.5%).
Valuation It trades at 24.5× forward earnings against a peer median of 18.8× (5th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 29.0 points above its cost of capital (5.0% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.45B | CN¥1.36B | CN¥1.20B | CN¥1.17B | CN¥960M |
| Revenue growth | — | +13% | +2% | +22% | — |
| Gross profit | CN¥990M | CN¥786M | CN¥703M | CN¥700M | CN¥555M |
| EBITDA | n/a | CN¥328M | CN¥295M | CN¥327M | CN¥261M |
| Net income | CN¥192M | CN¥149M | CN¥104M | CN¥128M | CN¥75.8M |
| Free cash flow | CN¥287M | CN¥291M | CN¥255M | CN¥264M | CN¥180M |
| Capital expenditure | CN¥26.4M | CN¥20.7M | CN¥26.0M | CN¥21.6M | CN¥26.3M |
| Total debt | CN¥645M | CN¥261M | CN¥312M | CN¥168M | CN¥184M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300622.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.5% | -3.6% | 3rd highest of 21 |
| 6-month return | -10.1% | -9.0% | 10th lowest of 21 |
| Distance from 52-week high | -42.7% | -24.9% | 5th lowest of 21 |
| Revenue growth (TTM) | +6.0% | +14.1% | 9th lowest of 21 |
| Operating margin | 14.3% | 9.5% | 8th highest of 21 |
| Forward P/E | 24.5× | 18.8× | 5th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | -2.4% | 9.2% | 3rd least demanding of 14 |
| Growth delivered (Del g) | +15.7% | +13.3% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -18.1 pp | -9.2 pp | 4th least demanding of 14 |
| ROIC minus cost of capital | +29.0 pp | +0.3 pp | 2nd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 24.5× | -2.4% | +15.7% |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | n/a | n/a | n/a |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | n/a | 33.5% | -0.6% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 32.4× | 13.5% | +13.3% |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 10.1× | -10.5% | +12.4% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 16.1× | -2.1% | +11.8% |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 19.8× | 0.1% | +15.6% |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 12.0× | n/a | n/a |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 20.3× | n/a | n/a |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $784M | -25% | +35% | 21% | 17.8× | -2.1% | +23.5% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 41.8× | 11.1% | +14.2% |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 24.1× | 16.7% | +25.9% |
| Standard Engineering Technology SETL.NS | India | $796M | +164% | +26% | 13% | n/a | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $798M | -27% | +40% | 10% | 12.5× | -8.0% | +6.6% |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | n/a | n/a | n/a |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 12.6× | 21.1% | +13.2% |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 11.8× | 0.1% | +40.3% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 30.0× | 21.1% | +24.2% |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | n/a | n/a | n/a |
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 164.7× | 9.2% | -10.2% |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | n/a | n/a | n/a |